分子性心肌成形术是治疗心肌异常性疾病的新方法。
Molecular cardiomyoplasty is a novel experimental strategy to treat myocardial abnormalities, such as myocardial infarction and heart failure.
这里对目前细胞性心肌成形术的移植细胞类型作一综述。
Here we will overview the different types of cells used for cardiac cell transplantation.
报告我国首例动力性心肌成形术应用的骨骼肌脉冲训练刺激方法。
The first case of dynamic cardiomyoplasty, using skeletal muscle pulse-training stimulation, in our country was reported.
慢性肾脏病患者发生心肌梗塞后死亡率很高，但其接受冠状动脉成形术的可能性远远小于非ckd患者。
Patients with chronic kidney disease (CKD) have high mortality following myocardial infarction (MI), but are less likely to undergo coronary angiography than those without CKD.
目的评价经皮冠脉腔内成形术(PTCA)及冠脉内支架术治疗急性心肌梗死的临床疗效。
Objective To evaluate the clinical efficiency of percutaneous transluminal coronary angioplasty (PTCA) and intracoronary stent on the treatment of acute myocardial infarction (AMI).
结论对急性心肌梗死患者实施不同再灌注治疗是安全有效的，应重视对合并心源性休克患者开展直接冠状动脉成形术和急症冠状动脉搭桥术。
Conclusions Reperfusion therapy is a safe and effective therapeutic maneuver for patient with AMI, moreover, primary PCI or emergency CABG may be more preferable in cardiac shock patients.
目的总结经皮腔内冠状动脉成形术（P TCA）及支架置入术治疗急性心肌梗死的结果和经验。
Objective To discuss the effect and experience in treating acute myocardial infarction by PTCA and stent implantation.
笔者总结了55例急性心肌梗死患者经皮冠状动脉腔内成形术（PTCA）及支架植入术中出现再灌注心律失常的防治、观察和护理。
The authors reported prevention, observation and nursing of reperfusion arrhythmia occurred in 55 patients with acute myocardial infarction undergoing PTCA and angioplasty implant.
并对冠状动脉成形术时药物心肌保护的意义、方法等进行了扼要的综述。
This paper reviews the significance and methodology of pharmacological myocardial protection during PTCA.
并对冠状动脉成形术时药物心肌保护的意义、方法等进行了扼要的综述。
This paper reviews the significance and methodology of pharmacological myocardial protection during PTCA.
应用推荐